


AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) A compound of formula I



or a pharmaceutically acceptable salt, hydrate, solvate or prodrug of the compound, wherein:

R¹ is hydrogen, -OH, -NO₂, -CN, -COOR, -OCH₂OR, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy or halo;

R is C₁-C₆ alkyl;

R² is a non-radioactive halo or a radioactive halo;

R³ is hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl; and

R⁴ is **hydrogen**, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon or is substituted with a radioactive halo when R² is a non-radioactive halo.

2. (Previously presented) The compound of claim 1, wherein:

R¹ is hydrogen, -OH, -CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy or halo; and

R⁴ is C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon.

3. (Previously presented) The compound of claim 2, wherein:

R¹ is hydrogen, -OH, -CN, -OCH₃, -CH₃ or -Br; and

R³ is hydrogen or -CH₃; and

R⁴ is -¹¹CH₃.

4. (Currently amended) The compound of claim 1, wherein:

R² is a non-radioactive halo or a radioactive halo, wherein the halo is iodo; and

R⁴ is ~~hydrogen~~, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon when R² is a non-radioactive halo.

5. (Previously presented) The compound of claim 4, wherein:

R is -CH₃; and

the radioactive carbon in R⁴ is ¹¹C.

6. (Currently amended) The compound of claim 5, wherein:

R¹ is -OH or C₁-C₆ alkoxy;

R² is a radioiodine; **[[and]]**

~~R³ and R⁴ are independently is~~ hydrogen or C₁-C₆ alkyl; and

R⁴ is C₁-C₆ alkyl.

7. (Currently amended) The compound of claim 6, wherein:

R¹ is -OH;

R² is -¹²³I or -¹²⁵I; and

~~R³ and R⁴ are each is~~ hydrogen.

8. (Original) The compound of claim 1, wherein R² is a radiofluoro.

9. (Currently amended) The compound of claim 8, wherein:

R¹ is -OH or C₁-C₆ alkoxy;

R² is ¹⁸F; [[and]]

R³ **and** R⁴ **are independently** is hydrogen or C₁-C₆ alkyl; **and**

R⁴ is C₁-C₆ alkyl.

10. (Previously presented) The compound of claim 9, wherein:

R¹ is -OH;

R³ is hydrogen; and

R⁴ is -CH₃.

11. (Previously presented) The compound of claim 1, wherein R⁴ is C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl, wherein the alkyl, alkenyl or alkynyl is substituted with a radioactive halo.

12. (Previously presented) The compound of claim 11, wherein:

R¹ is -OH or C₁-C₆ alkoxy;

R² is hydrogen;

R³ is hydrogen or C₁-C₆ alkyl; and

R⁴ is C₁-C₆ alkyl substituted with ¹⁸F.

13. (Previously presented) The compound of claim 12, wherein:

R¹ is -OH;

R³ is hydrogen; and

R⁴ is -CH₂CH₂CH₂¹⁸F.

14. (Original) A pharmaceutical composition comprising

(i) an effective amount of a compound of claim 1; and

(ii) a pharmaceutically acceptable carrier.

15. (Previously presented) A method for detecting amyloid deposit(s) *in vivo*, comprising:

- (i) administering to a mammal an effective amount of a compound of claim 1, wherein the compound would bind any amyloid deposit(s) in the mammal; and
- (ii) detecting binding of the compound to amyloid deposit(s) in the mammal.

16. (Previously presented) The method of claim 15, wherein the amyloid deposit(s) is/are located in the brain of the mammal.

17. (Previously presented) The method of claim 15, wherein the mammal is a human who is suspected of having Alzheimer's disease, familial Alzheimer's disease, Down's syndrome, Mild Cognitive Impairment or homozygotes for apolipoprotein E4 allele.

18. (Previously presented) The method of claim 15, wherein the detecting is effected by gamma imaging, magnetic resonance imaging or magnetic resonance spectroscopy.

19. (Previously presented) The method of claim 18, wherein the detecting is effected by gamma imaging.

20. (Previously presented) The method of claim 19, wherein the gamma imaging is PET or SPECT.

21. (Previously presented) The method of claim 15, wherein the compound is administered intravenously.

22. (Previously presented) A method for detecting amyloid deposit(s) *in vitro* comprising:

- (i) contacting a bodily tissue with an effective amount of a compound of claim 1, wherein the compound would bind any amyloid deposit(s) in the tissue; and
- (ii) detecting binding of the compound to amyloid deposit(s) in the tissue.

23. (Previously presented) The method of claim 22, wherein the compound is in a solution that further comprises 25-99% ethanol, with the remainder of the solution being water.

24. (Previously presented) The method of claim 23, wherein the solution comprises 0-50% ethanol and 0.0001 to 100 μ M of the compound.

25. (Previously presented) The method of claim 22 wherein the detecting is effected by bright-field, fluorescence, laser-confocal or cross-polarization microscopy.

26. (Previously presented) The method of claim 22, wherein the method further comprises:

(iii) separating from the tissue the amyloid deposit(s) bound to the compound; and

(iv) quantifying the amyloid deposit(s) bound to the compound.

27. (Previously presented) A method for distinguishing an Alzheimer's diseased brain from a normal brain comprising:

(i) obtaining tissues from (i) the cerebellum and (ii) another area of the same brain, of a normal mammal and of a mammal suspected of having Alzheimer's disease;

(ii) contacting the tissues with a compound of claim 1;

(iii) quantifying the amyloid bound to the compound;

(iv) calculating the ratio of (a) the amount of amyloid in the area of the brain other than the cerebellum to (b) the amount of amyloid in the cerebellum;

(v) comparing the ratio for a normal mammal with the ratio for a mammal suspected of having Alzheimer's disease.